<DOC>
	<DOCNO>NCT00006122</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody gemtuzumab ozogamicin locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining gemtuzumab ozogamicin chemotherapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness gemtuzumab ozogamicin without chemotherapy treat old patient acute myeloid leukemia .</brief_summary>
	<brief_title>Gemtuzumab Ozogamicin With Without Chemotherapy Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility , toxicity , antileukemic activity gemtuzumab ozogamicin ( CMA-676 ) without mitoxantrone , etoposide , cytarabine , idarubicin elderly patient acute myeloid leukemia . OUTLINE : This multicenter study . Patients stratify accord risk ( standard risk , define age 61-75 WHO performance status 0-1 v poor risk , define 75 year WHO performance status 0-2 OR 76 year WHO performance status 2 ) . Frontline therapy : Patients receive gemtuzumab ozogamicin IV 2 hour day 1 15 . Stratum I ( Standard risk patient ) : Patients disease progression time frontline therapy may begin induction therapy immediately . Induction therapy begin 7-10 day response assessment regardless response absence unacceptable toxicity . Stratum II ( Poor risk patient ) : Patients experience complete remission without platelet recovery begin consolidation therapy within 4-8 week response assessment absence unacceptable toxicity . Stratum I Induction therapy : Patients receive mitoxantrone IV 30 minute day 1 , 3 5 ; etoposide IV 1 hour day 1-3 ; cytarabine IV continuously day 1-7 . Patients experience partial response give second induction therapy course . Patients experience complete remission without platelet recovery 1 2 induction course begin consolidation therapy within 4-8 week response assessment absence unacceptable toxicity . Consolidation therapy : Patients receive idarubicin IV day 1 , 3 5 ; etoposide IV 1 hour day 1-3 ; cytarabine IV continuously day 1-5 . Stratum II Consolidation therapy : Patients receive gemtuzumab ozogamicin IV 2 hour day 1 1-3 month later . Patients follow monthly 1 year , every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 45-82 ( 28-49 stratum I , 17-33 stratum II ) patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary secondary acute myeloid leukemia ( AML ) Previously untreated At least 20 % marrow blast AML myelodysplastic syndrome allow No leukemia myeloproliferative diseases No acute promyelocytic leukemia ( M3 ) blastic phase chronic myelogenous leukemia No active CNS leukemia PATIENT CHARACTERISTICS : Age : 61 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics White blood count great 30,000/mm3 unless reducible less 30,000/mm3 maximum 7 day hydroxyurea Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) Renal : Creatinine great 3 time ULN Cardiovascular : No severe heart failure would preclude study Pulmonary : No severe lung failure would preclude study Other : No concurrent malignancies No active uncontrolled infection No concurrent severe neurological psychiatric disease No psychological , familial , sociological geographical condition would preclude compliance study HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : No prior humanize monoclonal antibody therapy Chemotherapy : Up 7 day prior hydroxyurea allow At least 24 hour since prior hydroxyurea No prior chemotherapy AML Endocrine therapy : No 7 day prior corticosteroids No prior endocrine therapy Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>